Article
PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients.
Hepatology (Baltimore, Md.) - 1 Aug 2013
Wedemeyer Heiner, Jensen Donald, Herring Robert, Ferenci Peter, Ma Mang-Ming, Zeuzem Stefan, Rodriguez-Torres Maribel, Bzowej Natalie, Pockros Paul, Vierling John, Ipe David, Munson Marie Lou, Chen Ya-Chi, Najera Isabel, Thommes James
Abstract excerpt
UNLABELLED: Mericitabine is a nucleoside analog polymerase inhibitor of hepatitis C virus (HCV). Treatment-naïve HCV genotype 1 or 4 patients were randomized to double-blind treatment with oral mericitabine at a dosage of 500 mg twice-daily (BID) for 12 weeks (A), 1,000 mg BID for 8 (B) or 12 weeks (C and D), or placebo BID for 12 weeks (E). All patients received pegylated interferon alpha-2a (Peg-IFNα-2a; 40...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.